Estimates Revisions Immix Biopharma, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
5.560 ^USD	+14.88%		+29.30%	+152.73%

Nov. 12	Immix Biopharma, Inc. Appoints Michael Grabow as Chief Commercial Officer	CI
Nov. 07	Immix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.
IMMIX BIOPHARMA, INC.	-	-
ARGENX SE
INSMED INCORPORATED
WUXI APPTEC CO., LTD.
BIONTECH SE
GENMAB A/S
WUXI BIOLOGICS (CAYMAN) INC.
SUMMIT THERAPEUTICS INC.
AKESO, INC.
MADRIGAL PHARMACEUTICALS, INC.
Average
Weighted average by Cap.